Sarepta Therapeutics (SRPT) Other Non-Current Liabilities (2012 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Other Non-Current Liabilities of $1.6 million for Q1 2026, down 96.53% year-over-year from $47.4 million in Q1 2025, and up 7.72% quarter-over-quarter from $1.5 million in Q4 2025.
Sarepta Therapeutics (SRPT) Other Non-Current Liabilities (2012 - 2026) Analysis & Trends
Sarepta Therapeutics' Other Non-Current Liabilities history runs 15 years deep, the most recent figure standing at $1.6 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 96.53% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $1.6 million (down 96.53% YoY), while the FY2025 annual figure was $1.5 million, down 96.77% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $1.6 million, up from $1.5 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $48.2 million in Q1 2024, with the low at $1.5 million in Q4 2025.
- The 5-year median for Other Non-Current Liabilities is $36.9 million (2022), against an average of $33.6 million.
- The sharpest annual moves came in 2023 and 2025: Other Non-Current Liabilities soared 235.45% in 2023, then tumbled 96.77% in 2025.
- Sarepta Therapeutics' Other Non-Current Liabilities stood at $36.9 million in 2022, then advanced by 3.25% to $38.1 million in 2023, then gained by 24.41% to $47.4 million in 2024, then sank by 96.77% to $1.5 million in 2025, then advanced by 7.72% to $1.6 million in 2026.
- Business Quant data shows SRPT's Other Non-Current Liabilities at $1.6 million in Q1 2026, $1.5 million in Q4 2025, and $36.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.83 Mn |
| Mar 31, 2026 | 1.65 Mn |
| Dec 31, 2025 | 1.53 Mn |
| Sep 30, 2025 | 36.30 Mn |
| Jun 30, 2025 | 47.40 Mn |
| Mar 31, 2025 | 47.40 Mn |
| Dec 31, 2024 | 47.40 Mn |
| Sep 30, 2024 | 47.40 Mn |
| Jun 30, 2024 | 48.20 Mn |
| Mar 31, 2024 | 48.20 Mn |
| Dec 31, 2023 | 38.10 Mn |
| Sep 30, 2023 | 38.10 Mn |
| Jun 30, 2023 | 36.10 Mn |
| Mar 31, 2023 | 36.90 Mn |
| Dec 31, 2022 | 36.90 Mn |
| Sep 30, 2022 | 36.90 Mn |
| Jun 30, 2022 | 11.00 Mn |
| Mar 31, 2022 | 11.00 Mn |
| Dec 31, 2021 | 43.60 Mn |
| Sep 30, 2021 | 43.60 Mn |